Skip to main content

Continuous Glucose Monitoring Can Predict Microvascular Complications in Type 1 Diabetes

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2025.

via HealthDay

WEDNESDAY, Jan. 22, 2025 -- Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin, according to a study published online Jan. 8 in Diabetes Technology & Therapeutics.

Boris P. Kovatchev, Ph.D., from the University of Virginia in Charlottesville, and colleagues examined the association of CGM metrics with microvascular complications of type 1 diabetes observed during the DCCT and established time-in-range (TIR) as a marker for glycemic control. Virtual CGM traces were added to the original DCCT data for each participant using a multistep machine-learning procedure.

The researchers found that TIR (70 to 180 mg/dL) computed from virtual CGM data for 14 days prior to each glycated hemoglobin measure reflected the observed differences in glycemic control between the intensive and conventional DCCT groups, with TIR >60 percent and <40 percent in these groups, respectively. TIR was associated with the risk for development or progression of retinopathy, nephropathy, and neuropathy, similar to glycated hemoglobin. TIR predicted retinopathy and microalbuminuria similarly to the original glycated hemoglobin data.

"We have demonstrated a strong association of TIR with the risk of development or progression of retinopathy and with the development of microalbuminuria," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Risk for Death, MACE Increased for Patients With Adult-Onset Type 1 Diabetes

FRIDAY, May 16, 2025 -- Adult-onset type 1 diabetes (T1D) is associated with an increased risk for death and major adverse cardiovascular events (MACE), according to a study...

Hyperglycemia, Insulin Resistance in Teens Linked to Worsening Cardiac Damage at Age 24

FRIDAY, May 9, 2025 -- Adolescent hyperglycemia and worsening insulin resistance (IR) are associated with an increased risk for worsening structural and functional cardiac damage...

Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes

TUESDAY, April 8, 2025 -- For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.